➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Harvard Business School
Colorcon
Medtronic
AstraZeneca

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HEXAMINOLEVULINATE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Hexaminolevulinate Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00052637 Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer Completed National Cancer Institute (NCI) Phase 3 2001-09-01 RATIONALE: Diagnostic procedures such as cystoscopy may improve the ability to detect cancer and to determine the extent of disease. PURPOSE: Diagnostic trial to compare the effectiveness of cystoscopy using hexyl 5-aminolevulinate and two light sources in detecting carcinoma in situ in patients who have bladder cancer.
NCT00052637 Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer Completed Photocure Phase 3 2001-09-01 RATIONALE: Diagnostic procedures such as cystoscopy may improve the ability to detect cancer and to determine the extent of disease. PURPOSE: Diagnostic trial to compare the effectiveness of cystoscopy using hexyl 5-aminolevulinate and two light sources in detecting carcinoma in situ in patients who have bladder cancer.
NCT00285701 Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study Completed KARL STORZ Endoscopy-America, Inc. Phase 1/Phase 2 2006-07-01 Patients referred for colon inspection (colonoscopy) due to suspicion of colon polyps/cancer will receive local administration of hexaminolevulinate (HAL) prior to colon inspection. Blue light illumination will induce red fluorescence of polyps and tumours, improving detection of the polyps and tumors. Different HAL doses will be tested to find the optimal image conditions. Tolerability measurements will be performed to ensure patient safety.
NCT00285701 Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study Completed Photocure Phase 1/Phase 2 2006-07-01 Patients referred for colon inspection (colonoscopy) due to suspicion of colon polyps/cancer will receive local administration of hexaminolevulinate (HAL) prior to colon inspection. Blue light illumination will induce red fluorescence of polyps and tumours, improving detection of the polyps and tumors. Different HAL doses will be tested to find the optimal image conditions. Tolerability measurements will be performed to ensure patient safety.
NCT00369018 A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions. Completed Photocure Phase 1/Phase 2 2006-08-01 The study will determine the best drug (MAL or HAL) dosage for photodynamic therapy of cervical precancerous lesions (dysplasia) in women that are referred for conisation (surgery).
NCT00634621 Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer Completed GE Healthcare N/A 2008-02-01 The purpose of this study is to determine the effectiveness of hexaminolevulinate (Hexvix) in the diagnosis and treatment of patients with non-invasive bladder cancer and if it results in a change in patient management.
NCT00708942 Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1 Terminated Photocure Phase 2 2009-01-01 The study will examine the effect of HAL vs placebo photodynamic therapy of low-grade cervical precancerous lesions (dysplasia) in women.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hexaminolevulinate Hydrochloride

Condition Name

Condition Name for Hexaminolevulinate Hydrochloride
Intervention Trials
Bladder Cancer 3
Cervical Intraepithelial Neoplasia 2
Colorectal Cancer 2
Colon Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hexaminolevulinate Hydrochloride
Intervention Trials
Cervical Intraepithelial Neoplasia 3
Urinary Bladder Neoplasms 3
Carcinoma in Situ 3
Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hexaminolevulinate Hydrochloride

Trials by Country

Trials by Country for Hexaminolevulinate Hydrochloride
Location Trials
Germany 5
Norway 4
France 2
Netherlands 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hexaminolevulinate Hydrochloride
Location Trials
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hexaminolevulinate Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Hexaminolevulinate Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hexaminolevulinate Hydrochloride
Clinical Trial Phase Trials
Completed 6
Terminated 2
Withdrawn 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hexaminolevulinate Hydrochloride

Sponsor Name

Sponsor Name for Hexaminolevulinate Hydrochloride
Sponsor Trials
Photocure 8
GE Healthcare 2
KARL STORZ Endoscopy-America, Inc. 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hexaminolevulinate Hydrochloride
Sponsor Trials
Industry 12
Other 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
McKinsey
McKesson
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.